Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $26.81 as of March 9th. PFE’s trailing and forward P/E were 19.89 and 9.14, respectively according to Yahoo Finance.
Photo by Spencer Davis on Unsplash
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. PFE delivered solid operational execution in fiscal 2025, successfully navigating the post-COVID transition while positioning itself for long-term growth.
Despite a 2% year-over-year revenue decline driven by the continued normalization of COVID products, the company’s core business demonstrated resilience, with non-COVID operational growth of 6% and adjusted EPS rising 4% to $3.22. Key growth drivers included Abrysvo, which surged 136% operationally, oncology biosimilars up 76%, and established franchises such as Eliquis, Prevnar, and Vyndaqel, which showed steady growth.
The oncology segment led the expansion, with double-digit growth across multiple therapies and a strengthened pipeline from recent Phase 3 successes, enhancing long-term revenue visibility. Specialty care and primary care franchises, while mixed, displayed durable performance, supporting the broader shift toward a diversified, innovation-led profile. Adjusted cost discipline was evident, with decreases in cost of sales, R&D, and SI&A, driving margin improvement and robust free cash flow.
However, GAAP results were heavily impacted by $4.4 billion in intangible asset impairments, restructuring, and other charges, creating persistent concerns about earnings quality. Pfizer’s capital allocation prioritized pipeline investment and deleveraging over share buybacks, with $10.4 billion in R&D and $8.8 billion in business development spend.
Guidance for 2026 anticipates stable revenues of $59.5–$62.5 billion, adjusted EPS of $2.80–$3.00, and continued pipeline-driven catalysts. Overall, Pfizer presents a cautiously bullish case for income-oriented investors, supported by a strong non-COVID growth trajectory, an advancing oncology pipeline, and resilient core franchises, while upside depends on continued execution and normalization of reported earnings.
Previously, we covered a bullish thesis on Pfizer Inc. (PFE) by Akim Guerreiro in September 2024, highlighting its high dividend yield, strong pipeline, and Seagen acquisition. PFE’s stock price has depreciated by approximately 8.05% since our coverage. Investomine shares a similar view but emphasizes Pfizer’s 2025 operational execution, post-COVID transition, and growth from non-COVID drivers like Abrysvo and oncology biosimilars.
Pfizer Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 81 hedge fund portfolios held PFE at the end of the fourth quarter which was 84 in the previous quarter. While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
